Benchmarking A Drug’s Performance Through Market Analysis

1. Benchmarking A Drug’s Performance Through Market Analysis Our client’s leading biologic treatment for moderate to severe atopic dermatitis (AD) continues to maintain its position in the German market. The 2023 analysis offers insights into its performance, competitive landscape, and healthcare professionals' (HCPs) attitudes toward the drug compared to alternatives. GrapheneAI’s advanced analytics, driven by AI, have the intelligence to leverage data from over 4 million dermatologists and 50 million patients. The AI’s ability to spontaneously discover insights allows it to capture unbiased perspectives from HCPs and patients alike, providing real-time and early reporting. This article delves into the data-driven benchmarking insights derived, examining the strengths and challenges faced by our client’s Med X in the German dermatology and immunology sectors. Med X’s Performance: Key Benchmarking Insights The benchmarking analysis of Med X’s performance in Q2 reveals both positive and negative trends in how it is perceived by dermatologists and immunologists in Germany. It remains a major player in the biologics market, often considered the first line of defense for severe atopic dermatitis. 1.Positive Attributes In Protocol 

2. Med X's inclusion in treatment protocols was a significant trigger for prescription, with 26.3% of HCPs highlighting this as a positive factor, a notable increase from the previous quarter. This reflects its established reputation and trust within the medical community. Good Skin Clearance  HCPs continue to recognize Med X’s efficacy in providing sustained relief and improving skin conditions. Though there was a minor decrease in some attributes, such as skin improvement and the mechanism of action, its ability to deliver substantial results still resonates with many HCPs. Steroid Sparing Effect  HCPs appreciate Med X’s steroid-sparing properties, which allow for safer, long-term use without the downsides associated with steroids. 2.Challenges and Negative Feedback Patient Compliance  One of the critical barriers to Med X's wider adoption is patient non-compliance with the injection routine. This issue was highlighted by 17.2% of HCPs, an increase of 11% from the previous quarter. The complexity of the treatment regimen may deter some patients from adhering to it, reducing its overall effectiveness. Adverse Events (AE/SAE)  Concerns over side effects, including hypersensitivity and the risk of adverse events, have been rising. These concerns are shared with Med Y, a class of drugs that are becoming an alternative to Med X for some patients. The risk of adverse events (18.7%) continues to be a significant consideration when prescribing Med X, particularly in comparison to emerging therapies. Lack of Understanding of Mechanism of Action (MoA)  Despite its effectiveness, Med X’s complex mechanism of action is not well understood by all HCPs, which poses a barrier to its broader use. Med X vs. Competitors: Biologics & Med Y The benchmarking analysis shows that Med X faces growing competition from both other biologics and Med Y, including its inhibitors. These treatments are gaining traction, especially among patients who are non-responders to Med X or who experience adverse events. 1.Med A: Aggressively positioning itself as an alternative to Med X, it has seen a significant increase in being considered the first-line biologic for maintenance therapy, with a remarkable 81.6% growth. However, it struggles to establish a clear advantage over Med X, particularly in areas like skin clearance, where it saw a 37.1% decline in perception. 2.Med Y: While still newer in the market, it is gaining attention as bridge therapies for AD patients. For instance, its inhibitors’ fast-acting skin improvement and efficacy as a monotherapy have made them viable alternatives in specific patient archetypes. However, safety concerns related to adverse events and the long-term effects of Med Y remain a key factor preventing broader adoption.

3. 3.Med Z: Another biologic in the market, continues to hold a strong position, particularly with its convenient dosing regimen. It is often considered in cases where Med X is not suitable, and its safety profile resonates with HCPs concerned about long-term treatment effects. Benchmarking Insights: Emotional Drivers & HCP Engagement Med X’s emotional connection with HCPs plays a significant role in its sustained success. According to the Q2 report, HCPs perceive the X team as responsive, with 17.4% of HCPs mentioning this as a driver for continued use, reflecting a 4.5% increase from the previous quarter. Long-term partnerships with dermatology and allergist associations also enhance its reputation among specialists, even though other areas, such as sustained relief and skin improvement, saw minor decreases. Some additional insights found are withheld for the reason of confidentiality. Benchmarking: Outlook and Considerations The competitive landscape for biologics and Med Y in the German market is intensifying, with all players vying for a share of the atopic dermatitis treatment niche. Med X remains a strong leader but must address challenges related to patient compliance, adverse events, and education on its mechanism of action to maintain its competitive edge. However, staying ahead of competitors will require ongoing engagement with HCPs, addressing concerns about side effects, and simplifying treatment protocols to enhance patient compliance. Contact us at GrapheneAI to get ahead and make better decisions with benchmarking insights.